ICON Receives High Ranking in Independent Industry Survey
Dublin, Ireland, May 11th, 2009 – ICON plc,
a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has again been named as a favourite Contract Research Organisation (CRO) to work with, according to a recent independent survey of pharmaceutical and biotechnology companies.
The fourth annual “CRO Industry Update”, conducted by William Blair & Company in association with CenterWatch, surveyed executives at 19 pharmaceutical and biotechnology companies regarding their experience with CROs and general trends affecting the CRO industry. ICON was among three CROs most frequently listed as sponsors’ favourite CRO in terms of quality, a result that is in line with ICON’s high rating in William Blair’s three previous CRO surveys. The report states that “ICON is consistently rated by our survey respondents as one of the highest-quality players in the space, despite its rapid growth,” and also describes how “this consistent quality bolsters our perception that ICON has one of the best growth profiles in the CRO industry, given its solid operations and relative size.”
The survey identified the most important metrics defining quality as budget maintenance, quality deliverables and delivery within timelines, followed by regulatory expertise, flexibility, customer service and low staff turnover.
Commenting on the results, Peter Gray, CEO ICON plc said “We are delighted to be consistently viewed by clients as a CRO that delivers quality service. We work extremely hard to maintain our quality standards and these survey results are testament to the great work and expertise of ICON employees. We remain committed to developing new ways to enable clients to bring their drugs and devices to market faster.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,100 employees, operating from 71 locations in 38 countries.
Further information is available at
www.iconplc.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
